Sabby Management’s Titan Pharmaceuticals TTNP Stock Holding History

Sabby Management’s Portfolio TTNP Stock Details TTNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-9	Closed	-$34K	–	215
2021 Q3	$34K	Sell	9 -55	-86%	-$2.41K	﹤0.01%	176
2021 Q2	$331K	Buy	64 +1	+2%	+$50	0.05%	119
2021 Q1	$376K	Buy	+63	New	+$4.17K	0.07%	121
2019 Q4	–	Hold	0	–	-$3K	–	88
2019 Q3	–	Sell	-3	Closed	-$1.35K	–	92
2019 Q2	$211K	Buy	3 +1	+50%	+$914	0.27%	57
2019 Q1	$184K	Buy	+2	New	+$1.94K	0.09%	53

Other funds holding TTNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

WPA

Winning Points Advisors Boca Raton, Florida $74.8M AUM

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return

Sabby Management's TTNP Position: Q4 2020 in Review

Sabby Management sold out of Titan Pharmaceuticals (TTNP) in Q4 2020, closing a stake of 8,095 shares — an estimated $803K sold.

Sabby Management first reported a position in TTNP in Q3 2018 and held it in 3 quarters. The position peaked at $803K in Q3 2020. 15 funds tracked by Wall St. Rank hold TTNP as of Q4 2020.

Sabby Management reported no remaining Titan Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
Sabby Management sold 8,095 Titan Pharmaceuticals shares in Q4 2020, an estimated $803K.
Sabby Management first reported a position in Titan Pharmaceuticals in Q3 2018 and held it in 3 quarters.
Sabby Management's Titan Pharmaceuticals position peaked at $803K in Q3 2020.
15 funds tracked by Wall St. Rank held Titan Pharmaceuticals as of Q4 2020.

Based on Sabby Management's 13F filing for Q4 2020, filed 16 Feb 2021.